<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01875978</url>
  </required_header>
  <id_info>
    <org_study_id>DMR101-IRB2-036</org_study_id>
    <nct_id>NCT01875978</nct_id>
  </id_info>
  <brief_title>Effect of Phytosterols on Nonalcoholic Fatty Liver Disease</brief_title>
  <official_title>Clinical Study of Phytosterols for Insulin-like Growth Factor-1 and Endothelial Progenitor Cell Levels in Patients With Nonalcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China Medical University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phytosterols are plant sterols . Phytosterols have anti-inflammation effect. Investigators
      have a hypothesis: phytosterols reduce oxidative stress , enhance Insulin-like growth
      factor-1(IGF-1) and endothelial progenitor cells(EPCs). Therefore, phytosterols has novel
      role in cardiovascular protection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fatty liver is the hepatic feature of metabolic syndrome. Metabolic syndrome increase the
      risk of atherosclerosis and cardiovascular disease. Adipose tissue secrete adipocytes
      accumulate in the liver result in fatty liver. Excess fat become low density
      lipoprotein-cholesterol(LDL-C) from liver. Oxidized- LDL-C adherence in the vessel result in
      atherosclerosis via inflammation and immune response.

      Phytosterols are present in the nuts, plant oil, broccoli and so on. The structure of
      phytosterols are similar with cholesterols. After the competition, the smaller absorption of
      cholesterols. Studies showed the average consumptions of phytosterols were 200mg daily but
      the enough amount for cardiovascular protection of phytosterols were 2000mg daily.

      Daily 2000mg phytosterols inhibit the absorption of intestine, reduce the LDL-C about 7-10%.
      Besides, phytosterols have the effect of anti-inflammation and anti-immune response. The
      anti-inflammation effect obvious inhibit the monocyte to transform to macrophage, inhibit the
      formation of foam cell.

      Clinical studies divided into two groups: 20/20 patients and 4 weeks follow up with
      cross-over test.First group A: Phytosterols 1800mg/day for 4 weeks ,washout 2 weeks, then
      placebo 4 weeks. Another group B: placebo 4 weeks, washout 2 weeks, then phytosterols 4
      weeks.Cross-over, double blind study was designed.

      Investigators check the possible benefits of LDL-C, Total -cholesterol,anti-oxidant
      capacity,C reactive protein,insulin-like growth factor-1, endothelial progenitor cells ; the
      possible side effect including liver function,muscle enzyme .
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolic Effect of Phytosterols on Patients With Nonalcoholic Fatty Liver Disease</measure>
    <time_frame>after 4 weeks phytosterols 1.8g/day</time_frame>
    <description>Check serum metabolic status: levels in total cholesterol, low density lipoprotein-cholesterol, fasting glucose
Check serum anti-inflammatory status: levels in C reactive protein
Mid-point: end of first intervention (Group A: after phytosterols, Group B: after placebo) End-point: end of second intervention (Group A: after placebo, Group B: after phytosterols)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-oxidative Capacity of Phytosterols on Patients With Fatty Liver Disease</measure>
    <time_frame>after 4 weeks phytosterols 1.8g/day</time_frame>
    <description>Check serum anti-oxidative capacity, especially the serum superoxide dismutase (SOD) levels.Serum SOD provide the anti-oxidative capacity in lipid oxidation.
Mid-point: end of first intervention (Group A: after phytosterols, Group B: after placebo) End-point: end of second intervention (Group A: after placebo, Group B: after phytosterols)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin-like Growth Factor-1 Effect of Phytosterols on Patients With Nonalcoholic Fatty Liver Disease</measure>
    <time_frame>after 4 weeks phytosterols 1.8g/day</time_frame>
    <description>Check serum Insulin-like growth factor-1 levels. Serum Insulin-like growth factor-1 (IGF-1) influence metabolic status and reduce EPCs apoptosis via IGF-1 receptor.
Mid-point: end of first intervention (Group A: after phytosterols, Group B: after placebo) End-point: end of second intervention (Group A: after placebo, Group B: after phytosterols)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endothelial Protective Effect of Phytosterols on Patients With Non-alcoholic Fatty Liver Disease</measure>
    <time_frame>after 4 weeks phytosterols 1.8g/day</time_frame>
    <description>Ceck serum endothelial progenitor cells in the monocytes group but not in the lymphocytes group. Serum EPCs in the monocytes group provide the effect of endothelial repair to support novel vessel protection.
Cytometry flow check 150,000 cells per time including monocytes and lymphocytes group. Positive cells is the EPCs in the monocytes group. Stain with KDR, call kinase insert domain receptor, also call as VEGF receptor-2.
Mid-point: end of first intervention (Group A: after phytosterols, Group B: after placebo) End-point: end of second intervention (Group A: after placebo, Group B: after phytosterols)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Phytosterols &amp; placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A:daily 1.8g phytosterols powder for 4 weeks first;group B:placebo for 4 weeks first</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Phytosterols &amp; placebo</intervention_name>
    <description>Group A:Phytosterols 1.8g/day with one meal for 4 weeks first;group B:placebo first</description>
    <arm_group_label>Phytosterols &amp; placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  (1)25-80 years

          -  (2)Fatty liver was diagnosed by abdominal echo by the same gastrologist, review by
             another gastrologist

        Exclusion Criteria:

          -  (1)Serological markers of hepatitis B virus(hepatitis B surface antigen and anti-HBs
             antibody) and hepatitis C virus infection (anti-HCV antibody)

          -  (2)Autoimmune liver disease or alcoholic liver disease(alcohol intake more than 20g
             per day by using a questionnaire)

          -  (3)Malignant diseases

          -  (4)Pregnancy or breast feeding

          -  (5)Clinical evidence of angina, congestive heart failure, valvular heart disease,
             inflammatory disease or thyroid dysfunction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dalong Chen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>China Medical University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2013</study_first_submitted>
  <study_first_submitted_qc>June 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2013</study_first_posted>
  <results_first_submitted>November 7, 2013</results_first_submitted>
  <results_first_submitted_qc>May 12, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 11, 2014</results_first_posted>
  <last_update_submitted>May 12, 2014</last_update_submitted>
  <last_update_submitted_qc>May 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phytosterols</keyword>
  <keyword>Endothelial progenitor cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study from Oct. to Dec.2012 in China Medical University Hospital -Taipei branch Initially,51 patients screened .Finally, 40 patients were enrolled.</recruitment_details>
      <pre_assignment_details>Statins, red yeast rice, omega-3 ,fibrates were excluded.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A:Phytosterols-placebo</title>
          <description>phytosterols 1.8g/day first, then placebo.</description>
        </group>
        <group group_id="P2">
          <title>Group B:Placebo-phytosterols</title>
          <description>Placebo first, then phytosterols 1.8g/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Study 4weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout 2 Weeks ,Crossover Study 4 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Fatty liver was diagnosed by abdominal echo, except hepatitis B,C,alcohol consumption. Totally 40 patients randomized divided to group A for phytosterols-placebo sequence and group B for placebo-phytosterols sequence.</population>
      <group_list>
        <group group_id="B1">
          <title>Group A:Phytosterols-placebo</title>
          <description>Daily 1.8g phytosterols powder for 4 weeks, washout 2weeks, then placebo for 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Group B:Placebo-phytosterols</title>
          <description>Placebo for 4 weeks, washout 2 weeks, then daily 1.8g phytosterols powder for 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" spread="12"/>
                    <measurement group_id="B2" value="51" spread="18"/>
                    <measurement group_id="B3" value="51" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Metabolic Effect of Phytosterols on Patients With Nonalcoholic Fatty Liver Disease</title>
        <description>Check serum metabolic status: levels in total cholesterol, low density lipoprotein-cholesterol, fasting glucose
Check serum anti-inflammatory status: levels in C reactive protein
Mid-point: end of first intervention (Group A: after phytosterols, Group B: after placebo) End-point: end of second intervention (Group A: after placebo, Group B: after phytosterols)</description>
        <time_frame>after 4 weeks phytosterols 1.8g/day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A:Phytosterols-placebo</title>
            <description>Daily 1.8g phytosterols powder for 4 weeks, washout 2weeks, then placebo for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Group B:Placebo-phytosterols</title>
            <description>Placebo for 4 weeks, washout 2 weeks, then daily 1.8g phytosterols powder for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolic Effect of Phytosterols on Patients With Nonalcoholic Fatty Liver Disease</title>
          <description>Check serum metabolic status: levels in total cholesterol, low density lipoprotein-cholesterol, fasting glucose
Check serum anti-inflammatory status: levels in C reactive protein
Mid-point: end of first intervention (Group A: after phytosterols, Group B: after placebo) End-point: end of second intervention (Group A: after placebo, Group B: after phytosterols)</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>total cholesterol (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184.1" spread="6.54"/>
                    <measurement group_id="O2" value="191.65" spread="8.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total cholesterol (mid-point)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174.60" spread="6.13"/>
                    <measurement group_id="O2" value="199.25" spread="6.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total cholesterol (end-point)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180.55" spread="5.59"/>
                    <measurement group_id="O2" value="188.60" spread="6.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>low density lipoprotein (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.33" spread="6.19"/>
                    <measurement group_id="O2" value="118.45" spread="7.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>low density lipoprotein (mid-point)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.76" spread="5.96"/>
                    <measurement group_id="O2" value="121.29" spread="6.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>low density lipoprotein (end-point)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.54" spread="5.05"/>
                    <measurement group_id="O2" value="112.66" spread="5.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fating glucose (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.23" spread="2.40"/>
                    <measurement group_id="O2" value="105.01" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fasting glucose (mid-point)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.78" spread="1.88"/>
                    <measurement group_id="O2" value="104.88" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fasting glucose (end-point)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.44" spread="2.36"/>
                    <measurement group_id="O2" value="101.65" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>c reactive protein (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="0.07"/>
                    <measurement group_id="O2" value="0.24" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>c reactive protein (mid-point)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.03"/>
                    <measurement group_id="O2" value="0.26" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C reactive protein (end-point)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.03"/>
                    <measurement group_id="O2" value="0.19" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis: phytosterols improve metabolic status</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>P-value &lt;0.05 is significance meaningful.</p_value_desc>
            <method>t-test, 1 sided</method>
            <method_desc>Student's t-test, 1 sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-oxidative Capacity of Phytosterols on Patients With Fatty Liver Disease</title>
        <description>Check serum anti-oxidative capacity, especially the serum superoxide dismutase (SOD) levels.Serum SOD provide the anti-oxidative capacity in lipid oxidation.
Mid-point: end of first intervention (Group A: after phytosterols, Group B: after placebo) End-point: end of second intervention (Group A: after placebo, Group B: after phytosterols)</description>
        <time_frame>after 4 weeks phytosterols 1.8g/day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A:Phytosterols-placebo</title>
            <description>phytosterols 1.8g/day first, then placebo.</description>
          </group>
          <group group_id="O2">
            <title>Group B:Placebo-phytosterols</title>
            <description>Placebo first, then phytosterols 1.8g/day</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-oxidative Capacity of Phytosterols on Patients With Fatty Liver Disease</title>
          <description>Check serum anti-oxidative capacity, especially the serum superoxide dismutase (SOD) levels.Serum SOD provide the anti-oxidative capacity in lipid oxidation.
Mid-point: end of first intervention (Group A: after phytosterols, Group B: after placebo) End-point: end of second intervention (Group A: after placebo, Group B: after phytosterols)</description>
          <units>U/mg-protein</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum SOD (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.33" spread="2.67"/>
                    <measurement group_id="O2" value="99.41" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum SOD (mid-point)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.91" spread="3.16"/>
                    <measurement group_id="O2" value="95.1" spread="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum SOD (end-point)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.28" spread="4.18"/>
                    <measurement group_id="O2" value="106.54" spread="3.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis: phytosterols increase the anti-oxidative capacity.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>P value &lt;0.05 for statistical significance</p_value_desc>
            <method>t-test, 1 sided</method>
            <method_desc>Student's t test, 1 sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin-like Growth Factor-1 Effect of Phytosterols on Patients With Nonalcoholic Fatty Liver Disease</title>
        <description>Check serum Insulin-like growth factor-1 levels. Serum Insulin-like growth factor-1 (IGF-1) influence metabolic status and reduce EPCs apoptosis via IGF-1 receptor.
Mid-point: end of first intervention (Group A: after phytosterols, Group B: after placebo) End-point: end of second intervention (Group A: after placebo, Group B: after phytosterols)</description>
        <time_frame>after 4 weeks phytosterols 1.8g/day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A:Phytosterols-placebo</title>
            <description>phytosterols 1.8g/day first, then placebo.</description>
          </group>
          <group group_id="O2">
            <title>Group B:Placebo-phytosterols</title>
            <description>Placebo first, then phytosterols 1.8g/day</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin-like Growth Factor-1 Effect of Phytosterols on Patients With Nonalcoholic Fatty Liver Disease</title>
          <description>Check serum Insulin-like growth factor-1 levels. Serum Insulin-like growth factor-1 (IGF-1) influence metabolic status and reduce EPCs apoptosis via IGF-1 receptor.
Mid-point: end of first intervention (Group A: after phytosterols, Group B: after placebo) End-point: end of second intervention (Group A: after placebo, Group B: after phytosterols)</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum IGF-1 (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.14" spread="8.36"/>
                    <measurement group_id="O2" value="153.30" spread="10.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum IGF-1 (mid-point)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167.96" spread="9.42"/>
                    <measurement group_id="O2" value="150.26" spread="9.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum IGF-1 (end-point)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.23" spread="7.78"/>
                    <measurement group_id="O2" value="178.04" spread="10.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phytosterols increase IGF-1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>P&lt;0.05 for statistical significance</p_value_desc>
            <method>t-test, 1 sided</method>
            <method_desc>Student's t test, 1 sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Endothelial Protective Effect of Phytosterols on Patients With Non-alcoholic Fatty Liver Disease</title>
        <description>Ceck serum endothelial progenitor cells in the monocytes group but not in the lymphocytes group. Serum EPCs in the monocytes group provide the effect of endothelial repair to support novel vessel protection.
Cytometry flow check 150,000 cells per time including monocytes and lymphocytes group. Positive cells is the EPCs in the monocytes group. Stain with KDR, call kinase insert domain receptor, also call as VEGF receptor-2.
Mid-point: end of first intervention (Group A: after phytosterols, Group B: after placebo) End-point: end of second intervention (Group A: after placebo, Group B: after phytosterols)</description>
        <time_frame>after 4 weeks phytosterols 1.8g/day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A:Phytosterols-placebo</title>
            <description>phytosterols 1.8g/day first, then placebo.</description>
          </group>
          <group group_id="O2">
            <title>Group B:Placebo-phytosterols</title>
            <description>Placebo first, then phytosterols 1.8g/day</description>
          </group>
        </group_list>
        <measure>
          <title>Endothelial Protective Effect of Phytosterols on Patients With Non-alcoholic Fatty Liver Disease</title>
          <description>Ceck serum endothelial progenitor cells in the monocytes group but not in the lymphocytes group. Serum EPCs in the monocytes group provide the effect of endothelial repair to support novel vessel protection.
Cytometry flow check 150,000 cells per time including monocytes and lymphocytes group. Positive cells is the EPCs in the monocytes group. Stain with KDR, call kinase insert domain receptor, also call as VEGF receptor-2.
Mid-point: end of first intervention (Group A: after phytosterols, Group B: after placebo) End-point: end of second intervention (Group A: after placebo, Group B: after phytosterols)</description>
          <units>positive cells/150,000 cells</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EPCs with CD34+ (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="2.38"/>
                    <measurement group_id="O2" value="18.4" spread="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EPCs with CD34+ (mid-point)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.35" spread="4.88"/>
                    <measurement group_id="O2" value="18.4" spread="3.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EPCs with CD34+ (end-point)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" spread="2.31"/>
                    <measurement group_id="O2" value="28.25" spread="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EPCs with CD34+,KDR+ (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.26"/>
                    <measurement group_id="O2" value="1.2" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EPCs with CD34+,KDR+ (mid-point)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="0.34"/>
                    <measurement group_id="O2" value="1.1" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EPCs with CD34+,KDR+ (end-point)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" spread="0.23"/>
                    <measurement group_id="O2" value="2.5" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EPCs with KDR+,CD133+ (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.24"/>
                    <measurement group_id="O2" value="1.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EPCs with KDR+,CD133+ (mid-point)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.45" spread="0.31"/>
                    <measurement group_id="O2" value="1.1" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EPCs with KDR+,CD133+ (end-point)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="0.26"/>
                    <measurement group_id="O2" value="2.4" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis:phytosterols increase endothelial progenitor cells to provide endothelial repair and vessel protection</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>P value &lt;0.05 for statistical significance</p_value_desc>
            <method>t-test, 1 sided</method>
            <method_desc>Student's t-test, 1 sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 months</time_frame>
      <desc>study 4 weeks, washout 2 weeks, then cross over study 4 weeks</desc>
      <group_list>
        <group group_id="E1">
          <title>Group A: Phytosterols-placebo</title>
          <description>Daily 1.8g phytosterols powder for 4 weeks, washout 2 weeks, then placebo for 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Group B: Placebo-phytosterols</title>
          <description>placebo for 4 weeks, washout 2 weeks. then daily 1.8 g phytosterols for 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Serious adverse event in the end of first intervention</sub_title>
                <description>Group A : after phytosterols, Group B: after placebo</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Serious adverse event in the end of second intervention</sub_title>
                <description>Group A: after placebo, Group B: after phytosterols</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea in the end of first intervention</sub_title>
                <description>Group A: after phytosterols, Group B: after placebo</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>diarrhea in the end of second intervention</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Group A: after placebo, Group B: after phytosterols</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The sample size of this study is small amount
Abdominal ultrasound related nonalcoholic fatty liver disease diagnosis is not compatible completely</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Dalong Chen</name_or_title>
      <organization>China Medical University Hospital</organization>
      <phone>+886-227919696 ext 1205</phone>
      <email>my686chen@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

